PDL Practice Alert


pdl logo

Important changes to legislation regarding pseudoephedrine and naloxone

On February 1, 2016, the scheduling on Naloxone changed from S4 to S3 for the treatment of opioid overdose. The two current suppliers of Naloxone have to this date not provided S3 packs so this means pharmacists supplying the product need to be aware of several factors for safe administration.

Firstly, the S4 pack must be labelled with a pharmacy dispensing label with the consumer name and directions for use. Most importantly, the pharmacist must be aware that the product does NOT contain a needle so either a 23Gauge or 25 Gauge needle of 25mm must be provided to the consumer. Also, be aware that one dose of Naloxne may not be sufficient so discuss with the consumer the need for having multiple doses on hand.

Consult professional practice guidelines for more information.

The second major change applies only to NSW regarding the provision of pseudoephedrine.

In that state, all pseudoephedrine products must be supplied via Project Stop from March 23rd. This will ensure that all sales are monitored by an online, real-time electronic system that will enable clinical decision making.

Please phone PDL on 1300 854 838 if you have any questions.

Previous Northern flu season a sign for Australia: Terry White Group
Next Clinical tips: osteoarthritis

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.